更新于：2024-11-01

Peripheral Stem Cell Transplantation

外周干细胞移植

更新于：2024-11-01

基本信息

别名

PBPC transplantation、PBSC - Peripheral blood stem cell graft、PBSC transplantation

+ [19]

简介

Transplantation of PERIPHERAL BLOOD STEM CELLS. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.

关联

项与外周干细胞移植相关的药物

Talquetamab

塔奎妥单抗

靶点

CD3 x GPRC5D

作用机制

CD3刺激剂 [+3]

在研机构

强生（中国）投资有限公司 [+7]

原研机构

Janssen Pharmaceuticals, Inc.

在研适应症

多发性骨髓瘤 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2023-08-09

Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc)

重组带状疱疹(GlaxoSmithKline Plc)

靶点-

作用机制

免疫刺激剂

在研机构

GlaxoSmithKline Biologicals SA [+7]

原研机构

GSK Plc

在研适应症

疱疹后神经痛 [+3]

非在研适应症

慢性淋巴细胞白血病 [+5]

最高研发阶段批准上市

首次获批国家/地区

加拿大

首次获批日期2017-10-13

Plerixafor

普乐沙福

靶点

CXCR4

作用机制

CXCR4拮抗剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2008-12-15

项与外周干细胞移植相关的临床试验

NCT03939585 / Not yet recruiting临床1期IIT

Preemptive Infusion of Donor Lymphocytes Depleted of TCR (Alpha-beta) + T Cells and CD19+ B Cells Following Allogeneic Stem Cell Transplantation

The purpose of this study is to reduce the risk of cancer relapse by giving a donor lymphocyte infusion (DLI) to boost the immune system early after a stem cell transplant so that leukemia cells that escaped chemotherapy can be detected and killed. This DLI will contain mostly lymphocytes that have graft versus tumor effect with low risk of graft versus host disease. Because the process of giving a DLI in the first four weeks after a transplant has not been approved by the Food and Drug Administration (FDA), this study in investigational (experimental).

开始日期2024-12-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT06461988 / Not yet recruiting临床2期IIT

An Open-Label, Non-Randomized, Multicenter, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)

Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal proliferation of plasma cells and organ damage. Autologous transplantation with high dose chemotherapy is the standard of care in frontline treatment of eligible patients with MM.

开始日期2024-11-01

申办/合作机构

Stanford University

[+1]

TCTR20240612001 / RecruitingN/AIIT

Comparison of the effectiveness of cryopreserved versus fresh peripheral blood allogenic stem cell transplantation at Siriraj hospital

开始日期2024-03-04

申办/合作机构-

100 项与外周干细胞移植相关的临床结果

登录后查看更多信息

100 项与外周干细胞移植相关的转化医学

登录后查看更多信息

0 项与外周干细胞移植相关的专利（医药）

登录后查看更多信息

项与外周干细胞移植相关的文献（医药）

2017-11-02·Journal of Psychosocial Oncology4区 · 医学

Personal resilience resources predict post-stem cell transplant cancer survivors' psychological outcomes through reductions in depressive symptoms and meaning-making

4区 · 医学

Article

作者: Austin, Jane ; Campo, Rebecca A. ; Valdimarsdottir, Heiddis ; Rini, Christine ; Wu, Lisa M.

This longitudinal study examined whether post-transplant cancer survivors (N = 254, 9 months to 3 years after stem cell transplant treatment) with greater personal resilience resources demonstrated better psychological outcomes and whether this could be attributed to reductions in depressive symptoms and/or four meaning-making processes (searching for and finding reasons for one's illness; searching for and finding benefit from illness). Hierarchical linear regression analyses examined associations of survivors' baseline personal resilience resources (composite variable of self-esteem, mastery, and optimism), which occurred an average of 1.7 years after transplant, and 4-month changes in psychological outcomes highly relevant to recovering from this difficult and potentially traumatic treatment: post-traumatic stress disorder (PTSD) symptoms and purpose in life. Boot-strapped analyses tested mediation. Greater personal resilience resources predicted decreases in PTSD stress symptoms (b = -0.07, p = 0.005), mediated by reductions in depressive symptoms (b = -0.01, 95% CI: -0.027, -0.003) and in searching for a reason for one's illness (b = -0.01, 95% CI: -0.034, -0.0003). In addition, greater resilience resources predicted increases in purpose in life (b = 0.10, p < 0.001), mediated by reductions in depressive symptoms (b = 0.02, 95% CI: 0.003, 0.033). Having greater personal resilience resources may promote better psychological adjustment after a difficult cancer treatment, largely because of improvements in depressive symptoms, although decreased use of a potentially maladaptive form of meaning-making (searching for a reason for one's illness) was also important for reducing PTSD symptoms.

2017-02-01·Annals of the American Thoracic Society

Rapid Onset of Hypoxemia in a Man with Graft-versus-Host Disease after Stem Cell Transplant Leukemia

Article

作者: Nguyen, Nathan ; Karamooz, Elham ; Gold, Jeffrey A.

Archivos de la Sociedad Española de Oftalmología

Empleo de interferón alfa-2b para el tratamiento de carcinomas conjuntivales intraepiteliales en casos seleccionados

Article

作者: D Díaz Valle ; S Lorenzo Giménez ; L Cortés Lambea ; N Toledano Fernández ; A Arteaga Sánchez ; S García Sáenz ; M Segura Bedmar

PURPOSETo study the efficacy of topical and combined topical and subconjunctival interferon alfa 2b (IFN alfa 2b) in the treatment of recurrent conjunctival intraepithelial neoplasia (CIN) in those patients who present resistance or intolerance to topical mitomycin C (MMC) treatment or when it is not indicated.METHODSFour patients (age range from 52 to 70) with histological confirmation of recurrent CIN were studied prospectively. Two patients were resistant to topical MMC, another one did not tolerate it, and in the last case, this treatment was not indicated due to a stem cell insufficiency associated to a trophic corneal ulcer. Three patients were given just topical interferon (1 million IU/ ml four times a day for three months), while the last one received topical therapy and subconjunctival IFN alfa 2b injections (3 millions IU/ 0.5 ml).RESULTSComplete regression of the tumour was evident in all cases. sixteen to 24 months after treatment no patient had clinical evidence of recurrence. No side effects were observed in any patient, not even with subconjunctival administration.CONCLUSIONSIFN alfa 2b is effective as an alternative treatment to topical MMC in selected cases of recurrent CIN.